Bullish Moving Averages
6
Bearish Moving Averages
10
Back Stocks profile
Stock analysis tool for investors
Open an Account with Bigul in 5 minutes
Performance
Today’s low
6647.00Today’s High
6699.0052W low
5205.6052W High
7107.40Open Price
6686.40Prev. Close
6683.8500Volume
245612.00Value
1635947848.40Fundamentals
Market Cap
111147.00
Price to Earnings
20.00
Price to Book Value
3.90
Dividend Yield
0.60
PE to Growth
1.10
Op Revenue TTM
28949.30
Net Profit TTM
5565.30
Cash From Operating Activity
4543.30
Return on Equity %
19.74
EMA & SMA
DELIVERY AND VOLUME
DAILY AVG. DELIVERY VOLUME %
13 Sep, 2024
71.3
Week
56.2
Month
60
LEGEND
Positive Indicator
Neutral Indicator
Negative Indicator
RESISTANCE AND SUPPORT
6668.92
PIVOT
First Resistance
6690.83
Second Resistance
6720.97
Third Resistance
6742.88
First Support
6638.78
Second Support
6616.87
Third Support
6586.73
Relative Strength Index
41.66
Money Flow Index
39.68
MACD
-45.27
MACD Signal
-8.25
Average True Range
115.87
Average Directional Index
21.76
Rate of Change (21)
-2.06
Rate of Change (125)
5.69
Day Commodity Channel Index
-94.2
Day Williams %R
-83.8
BETA
1 Month
0.36
3 Month
0.48
1 Year
0.4
3 Year
0.04
PRICE CHANGE ANALYSIS
↓ -0.52%
1 Week
Low
High
6580.3
6749.35
↓ -3.28%
1 Month
Low
High
6580.3
7107.45
↑ 9.91%
3 Months
Low
High
5888
7107.45
↑ 5.69%
6 Months
Low
High
5600
7107.45
↑ 17.39%
1 Year
Low
High
5205.55
7107.45
| Indicator | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | Dec 2021 | Sep 2021 | Jun 2021 | Graph |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Qtr Revenue cr | 6059.00 | 5317.50 | 4330.60 | 5061.80 | 5670.90 | 4668.80 | 3949.00 | 4998.30 | 4034.00 | 3783.40 | 3542.60 | 3941.50 | 3619.70 | |
| Operating Expenses Qtr | 3888.20 | 3700.20 | 3446.70 | 3209.60 | 3209.60 | 3488.80 | 3221.50 | 3077.50 | 3051.10 | 2989.00 | 2865.60 | 3075.10 | 2871.60 | |
| Operating Profit Qtr | 1953.00 | 1378.60 | 656.30 | 1629.10 | 2227.70 | 1061.10 | 675.10 | 1802.80 | 579.50 | 669.90 | 614.00 | 748.30 | 561.90 | |
| EBIDT Qtr Cr | 2170.80 | 1591.30 | 883.90 | 1852.20 | 2461.30 | 1175.90 | 726.50 | 1920.80 | 982.90 | 784.60 | 677.00 | 866.40 | 748.10 | |
| Depreciation Qtr | 249.80 | 246.20 | 246.40 | 245.80 | 237.20 | 236.70 | 238.80 | 226.20 | 221.50 | 205.20 | 205.40 | 206.60 | 197.10 | |
| Net Profit Qtr | 1417.20 | 1034.80 | 475.20 | 1192.60 | 1639.40 | 672.40 | 324.60 | 1116.30 | 499.50 | 419.70 | 341.10 | 449.00 | 413.40 | |
| Basic EPS Qtr | 85.10 | 62.14 | 28.55 | 71.68 | 98.66 | 40.49 | 19.54 | 67.25 | 30.10 | 25.29 | 20.55 | 27.07 | 24.94 |
| Indicator | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Graph |
|---|---|---|---|---|---|---|
| Total Revenue Annual | 20346.10 | 17553.80 | 14887.20 | 14150.20 | 12593.60 | |
| Operating Expenses Annual Cr | 13557.40 | 12747.70 | 11811.10 | 10212.30 | 8980.80 | |
| Operating Profit Annual | 5926.40 | 4214.80 | 2594.10 | 3136.80 | 2869.60 | |
| Operating Profit Margin Annual % | 29.13 | 24.01 | 17.43 | 22.17 | 22.79 | |
| Total Expenses Annual Cr | 14554.80 | 13687.80 | 12663.40 | 11094.00 | 9817.80 | |
| EBIDT Annual Cr | 6788.70 | 4806.10 | 3076.10 | 3937.90 | 3612.80 | |
| EBIDT Annual margin % | 33.37 | 27.38 | 20.66 | 27.83 | 28.69 | |
| Depreciation | 975.60 | 923.20 | 814.30 | 835.00 | 789.20 | |
| PAT Before ExtraOrdinary Items Annual Cr | 4342.00 | 2612.80 | 1623.20 | 2186.40 | 2937.70 | |
| Net Profit Annual | 4342.00 | 2612.80 | 1623.20 | 2186.40 | 2937.70 | |
| Basic EPS Annual | 260.95 | 157.37 | 97.85 | 131.84 | 177.23 |
| Indicator | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Graph |
|---|---|---|---|---|---|---|
| Total ShareHolders Funds Annual | 24240.80 | 20474.20 | 18336.20 | 16983.70 | 15191.90 | |
| Minority Interest Liability Annual Cr | - | - | - | - | - | |
| Total Non Current Liabilities Annual Cr | 580.40 | 460.90 | 114.30 | 85.60 | 103.40 | |
| Total Current Liabilities Annual Cr | 5538.10 | 4439.70 | 6045.10 | 4560.30 | 4180.50 | |
| Total Capital Plus Liabilities Annual Cr | 30359.30 | 25374.80 | 24495.60 | 21629.60 | 19475.80 | |
| Fixed Assets Annual | 8800.10 | 8119.70 | 7350.80 | 6745.10 | 4845.70 | |
| Total Non Current Assets Annual | 12543.40 | 11586.50 | 11012.00 | 10685.40 | 9369.10 | |
| Total Current Assets Annual | 17815.90 | 13788.30 | 13483.60 | 10944.20 | 10106.70 | |
| Total Assets Annual | 30359.30 | 25374.80 | 24495.60 | 21629.60 | 19475.80 | |
| Contingent Liabilities plus Commitments Annual Cr | 1763.60 | 830.20 | 827.40 | 1062.80 | 1068.60 |
| Indicator | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Graph |
|---|---|---|---|---|---|---|
| Cash from Operating Activity Annual | 3449.70 | 5052.90 | 1338.70 | 3514.20 | 1839.20 | |
| Cash from Investing Activity Annual | -3430.30 | -3447.60 | -2038.00 | -1458.00 | -1689.20 | |
| Cash from Financing Annual Activity | 68.10 | -2696.90 | 505.50 | -794.30 | -224.10 | |
| Net Cash Flow Annual | 87.50 | -1091.60 | -193.80 | 1261.90 | -74.10 |
| Indicator | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Graph |
|---|---|---|---|---|---|---|
| Book Value Per Share Annual | 1453.29 | 1228.94 | 1101.93 | 1020.65 | 914.07 | |
| ROE Annual % | 17.91 | 12.76 | 8.85 | 12.87 | 19.33 | |
| ROCE Annual % | 23.41 | 18.54 | 12.25 | 18.17 | 18.46 | |
| Total Debt to Total Equity Annual | 0.03 | 0.00 | 0.12 | 0.07 | 0.07 | |
| EBDIT Annual Margin % | 34.84 | 28.33 | 21.35 | 29.49 | 30.48 |
| Indicator | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | Dec 2021 | Sep 2021 | Jun 2021 | Graph |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Qtr Revenue cr | 7883.30 | 7311.30 | 7453.00 | 7217.60 | 6931.90 | 6453.70 | 6848.50 | 6372.60 | 6086.80 | 5596.80 | 5394.10 | 5992.40 | 5053.00 | |
| Operating Expenses Qtr | 5566.20 | 5299.90 | 5213.70 | 4888.80 | 4694.70 | 4727.30 | 4837.90 | 4430.40 | 4291.70 | 4282.00 | 4117.90 | 4427.10 | 4210.60 | |
| Operating Profit Qtr | 2129.90 | 1831.20 | 2023.10 | 2008.30 | 2062.10 | 1533.90 | 1938.50 | 1898.90 | 941.20 | 451.00 | 1215.70 | 1359.80 | 734.50 | |
| EBIDT Qtr Cr | 2317.10 | 2028.70 | 2239.30 | 2323.30 | 2236.10 | 1672.40 | 1997.20 | 1939.70 | 1795.10 | 572.90 | 1271.50 | 1565.30 | 842.40 | |
| Depreciation Qtr | 380.60 | 367.70 | 373.50 | 375.50 | 353.30 | 315.50 | 323.70 | 309.20 | 301.80 | 293.00 | 294.20 | 294.10 | 283.90 | |
| Net Profit Qtr | 1392.40 | 1309.80 | 1380.90 | 1482.20 | 1405.00 | 960.10 | 1243.90 | 1114.20 | 1189.00 | 97.00 | 709.30 | 995.80 | 380.40 | |
| Basic EPS Qtr | 83.61 | 78.66 | 82.94 | 89.09 | 84.55 | 57.79 | 74.91 | 67.13 | 71.64 | 5.84 | 42.75 | 60.03 | 22.95 |
| Indicator | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Graph |
|---|---|---|---|---|---|---|
| Total Revenue Annual | 28905.40 | 25725.20 | 22029.60 | 19338.90 | 18137.60 | |
| Operating Expenses Annual Cr | 20078.00 | 18320.70 | 17777.50 | 15177.60 | 15046.60 | |
| Operating Profit Annual | 7933.10 | 6349.00 | 3767.70 | 3869.90 | 2470.40 | |
| Operating Profit Margin Annual % | 27.45 | 24.68 | 17.10 | 20.01 | 13.62 | |
| Total Expenses Annual Cr | 21719.10 | 19713.70 | 19038.50 | 16503.40 | 16308.00 | |
| EBIDT Annual Cr | 8827.40 | 7404.50 | 4252.10 | 4161.30 | 3091.00 | |
| EBIDT Annual margin % | 30.54 | 28.78 | 19.30 | 21.52 | 17.04 | |
| Depreciation | 1470.00 | 1250.20 | 1165.20 | 1228.80 | 1163.10 | |
| PAT Before ExtraOrdinary Items Annual Cr | 5563.20 | 4470.30 | 2112.20 | 1903.60 | 1969.90 | |
| Net Profit Annual | 5577.90 | 4507.30 | 2182.50 | 1951.60 | 2026.00 | |
| Basic EPS Annual | 335.22 | 271.47 | 131.21 | 117.34 | 121.99 |
| Indicator | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Graph |
|---|---|---|---|---|---|---|
| Total ShareHolders Funds Annual | 28254.80 | 23286.10 | 19212.40 | 17641.70 | 15598.80 | |
| Minority Interest Liability Annual Cr | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Total Non Current Liabilities Annual Cr | 1021.00 | 426.90 | 768.70 | 871.30 | 412.40 | |
| Total Current Liabilities Annual Cr | 9588.00 | 8572.10 | 9765.80 | 8103.80 | 7214.10 | |
| Total Capital Plus Liabilities Annual Cr | 38863.80 | 32285.10 | 29746.90 | 26616.80 | 23225.30 | |
| Fixed Assets Annual | 11294.80 | 9701.80 | 8867.60 | 9210.90 | 7894.10 | |
| Total Non Current Assets Annual | 14058.50 | 11859.60 | 11964.60 | 12066.50 | 10626.20 | |
| Total Current Assets Annual | 24805.30 | 20425.50 | 17782.30 | 14550.30 | 12599.10 | |
| Total Assets Annual | 38863.80 | 32285.10 | 29746.90 | 26616.80 | 23225.30 | |
| Contingent Liabilities plus Commitments Annual Cr | 2091.80 | 997.40 | 936.80 | 1077.40 | 1040.60 |
| Indicator | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Graph |
|---|---|---|---|---|---|---|
| Cash from Operating Activity Annual | 4543.30 | 5887.50 | 2810.80 | 3570.30 | 2984.10 | |
| Cash from Investing Activity Annual | -4028.30 | -4137.30 | -2638.70 | -2266.00 | -492.30 | |
| Cash from Financing Annual Activity | -376.30 | -2686.10 | -242.20 | -29.80 | -2515.90 | |
| Net Cash Flow Annual | 138.70 | -935.90 | -70.10 | 1274.50 | -24.10 |
| Indicator | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Graph |
|---|---|---|---|---|---|---|
| Book Value Per Share Annual | 1693.93 | 1397.72 | 1154.59 | 1060.20 | 938.56 | |
| ROE Annual % | 19.74 | 19.35 | 11.35 | 11.06 | 12.98 | |
| ROCE Annual % | 25.13 | 25.95 | 15.44 | 15.84 | 12.04 | |
| Total Debt to Total Equity Annual | 0.06 | 0.05 | 0.16 | 0.15 | 0.11 | |
| EBDIT Annual Margin % | 31.51 | 30.01 | 19.73 | 21.84 | 17.64 |
| Name | Holding Percent | Holding Id | Pledged % | Locked % |
|---|---|---|---|---|
| HDFC TRUSTEE COMPANY LTD. A/C HDFC NIFTY 50 ETF | 1.75 | 89016255 | - | - |
| SBI NIFTY INDEX FUND | 1.29 | 89016256 | - | - |
| ICICI PRUDENTIAL VALUE DISCOVERY FUND | 1.17 | 89016257 | - | - |
| NPS TRUST-A/C SBI PENSION FUND SCHEME TAX SAVER-TIER 2 | 2.53 | 89016263 | - | - |
| Name | Holding Percent | Holding Id | Pledged % | Locked % |
|---|---|---|---|---|
| G V PRASAD | 11.52 | 89016238 | 0 | 0 |
| SATISH REDDY KALLAM | 9.61 | 89016239 | 0 | 0 |
| KALLAM SATISH REDDY HUF | 3.31 | 89016240 | 0 | 0 |
| GUNUPATI VENKATESWARA PRASAD HUF | 1.52 | 89016241 | 0 | 0 |
| SAMRAJYAM REDDY KALLAM | 0.67 | 89016242 | 0 | 0 |
| Name | Holding Percent | Holding Id |
|---|---|---|
| HDFC TRUSTEE COMPANY LTD. A/C HDFC NIFTY 50 ETF | 1.75 | 89016255 |
| SBI NIFTY INDEX FUND | 1.29 | 89016256 |
| ICICI PRUDENTIAL VALUE DISCOVERY FUND | 1.17 | 89016257 |
| MIRAE ASSET NIFTY INDIA MANUFACTURING ETF | 1.11 | 89016258 |
| NIPPON LIFE INDIA TRUSTEE LTD-A/C-NIPPON INDIA NIFTY 50 VALUE 20 INDEX FUND | 1.02 | 89016259 |
| FIRST SENTIER INVESTORS ICVC - STEWART INVESTORS ASIA PACIFIC LEADERS SUSTAINABILITY FUND | 2.32 | 89016269 |
| LIFE INSURANCE CORPORATION OF INDIA P & GS FUND | 5.52 | 89016261 |
| J P Morgan Chase Bank NA | 14.59 | 89016266 |
| NPS TRUST-A/C SBI PENSION FUND SCHEME TAX SAVER-TIER 2 | 2.53 | 89016263 |
| Name | Holding Percent | Holding Id |
|---|
| Ex-Date | Dividend Amount | Dividend Type | Record Date | Instrument Type |
|---|---|---|---|---|
| Jul 16, 2024 | 40 | FINAL | - | Equity Share |
| Jul 11, 2023 | 40 | FINAL | - | Equity Share |
| Jul 11, 2022 | 30 | FINAL | - | Equity Share |
| Jul 09, 2021 | 25 | FINAL | - | Equity Share |
| Jul 13, 2020 | 25 | FINAL | - | Equity Share |
| Jul 15, 2019 | 20 | FINAL | - | Equity Share |
| Jul 16, 2018 | 20 | FINAL | - | Equity Share |
| Jul 17, 2017 | 20 | FINAL | - | Equity Share |
| Jul 18, 2016 | 20 | FINAL | - | Equity Share |
| Jul 10, 2015 | 20 | FINAL | - | Equity Share |
| Jul 11, 2014 | 18 | FINAL | - | Equity Share |
| Jul 12, 2013 | 15 | FINAL | - | Equity Share |
| Jun 28, 2012 | 13.75 | FINAL | - | Equity Share |
| Jun 30, 2011 | 11.25 | FINAL | - | Equity Share |
| Jul 02, 2010 | 11.25 | FINAL | - | Equity Share |
| Jul 03, 2009 | 6.25 | FINAL | - | Equity Share |
| Jul 04, 2008 | 3.75 | FINAL | - | Equity Share |
| Jul 06, 2007 | 3.75 | FINAL | - | Equity Share |
| Jul 07, 2006 | 5 | FINAL | - | Equity Share |
| Jul 07, 2005 | 5 | FINAL | - | Equity Share |
| Jul 13, 2004 | 5 | FINAL | - | Equity Share |
| Aug 08, 2003 | 5 | FINAL | - | Equity Share |
| Aug 08, 2002 | - | FINAL | - | Equity Share |
| Nov 08, 2001 | - | INTERIM | Nov 26, 2001 | Equity Share |
| Jun 18, 2001 | - | FINAL | - | Equity Share |
| Sep 07, 2000 | - | FINAL | - | Equity Share |
| Ex-Date | Split Ratio | Record Date |
|---|---|---|
| Oct 10, 2001 | 10:5 | 2001-10-25 |
| Ex-Date | Purpose | Notes |
|---|---|---|
| Jul 27, 2024 | Quarterly Results & Stock Split | - |
| May 07, 2024 | Audited Results & Final Dividend | - |
| Jan 30, 2024 | Quarterly Results | - |
| Oct 27, 2023 | Quarterly Results | - |
| Jul 26, 2023 | Quarterly Results | - |
| May 10, 2023 | Audited Results & Final Dividend | - |
| Jan 25, 2023 | Quarterly Results | - |
| Oct 28, 2022 | Quarterly Results | - |
| Jul 28, 2022 | Quarterly Results | - |
| May 19, 2022 | Audited Results & Final Dividend | - |
| Jan 28, 2022 | Quarterly Results | - |
| Oct 29, 2021 | Quarterly Results | - |
| Jul 27, 2021 | Quarterly Results | - |
| May 14, 2021 | Audited Results & Final Dividend | - |
| Jan 29, 2021 | Quarterly Results | - |
| Oct 28, 2020 | Quarterly Results | - |
| Jul 29, 2020 | Quarterly Results | - |
| May 20, 2020 | Audited Results & Final Dividend | (Revised) |
| May 13, 2020 | Audited Results & Final Dividend | - |
| Mar 27, 2020 | Others | Inter alia, to consider and approve Raising of funds through issuance of Commercial Papers. |
| Jan 27, 2020 | Quarterly Results | - |
| Nov 01, 2019 | Quarterly Results | - |
| Jul 29, 2019 | Quarterly Results | - |
| May 17, 2019 | Audited Results & Final Dividend | - |
| Feb 01, 2019 | Quarterly Results | - |
| Oct 26, 2018 | Quarterly Results | - |
| Jul 26, 2018 | Quarterly Results | - |
| May 22, 2018 | Audited Results & Dividend | - |
| Jan 25, 2018 | Quarterly Results | - |
| Oct 31, 2017 | Quarterly Results | - |
| Jul 27, 2017 | Quarterly Results | - |
| May 12, 2017 | Audited Results & Dividend | - |
| Feb 04, 2017 | Quarterly Results | - |
| Oct 25, 2016 | Quarterly Results | - |
| Jul 26, 2016 | Quarterly Results | - |
| May 12, 2016 | Audited Results & Dividend | - |
| Feb 17, 2016 | Buy Back of Shares | - |
| Feb 09, 2016 | Quarterly Results | - |
| Oct 29, 2015 | Quarterly Results | - |
| Jul 30, 2015 | Quarterly Results | - |
| May 12, 2015 | Audited Results & Final Dividend | - |
| Jan 29, 2015 | Quarterly Results | - |
| Oct 29, 2014 | Quarterly Results | - |
| Jul 30, 2014 | Quarterly Results | - |
| May 13, 2014 | Audited Results & Dividend | - |
| Feb 11, 2014 | Quarterly Results | - |
| Oct 31, 2013 | Quarterly Results | - |
| Jul 30, 2013 | Quarterly Results | - |
| May 14, 2013 | Audited Results & Dividend | - |
| Feb 14, 2013 | Quarterly Results | - |
| Oct 30, 2012 | Quarterly Results | - |
| Jul 19, 2012 | Quarterly Results | - |
| May 11, 2012 | Audited Results & Dividend | - |
| Feb 03, 2012 | Quarterly Results | - |
| Oct 25, 2011 | Quarterly Results | - |
| Jul 20, 2011 | Quarterly Results | - |
| May 13, 2011 | Audited Results & Dividend | - |
| Jan 25, 2011 | Quarterly Results | - |
| Oct 23, 2010 | Quarterly Results | - |
| Jul 22, 2010 | Quarterly Results | - |
| May 06, 2010 | Audited Results, Dividend & ESOP | To grant of 16,800 stock options, exercisable at par value of Rs. 5/- to the Independent Directors of the Co. under "Dr. Reddy's ESOS, 2002" & "Dr. Reddy's Employees ADR Stock Option Scheme, 2007". |
| Mar 31, 2010 | Issuance of Bonus Debentures | For issuance of bonus debentures to Shareholders of the Co. from its General Reserves built from undistributed profits, The allotment of debentures will account for an amount not exceeding Rs. 520 Cr. |
| Jan 20, 2010 | Quarterly Results | - |
| Oct 23, 2009 | Quarterly Results | - |
| Jul 21, 2009 | Quarterly Results | - |
| May 18, 2009 | Audited Results, Dividend & Others | To grant of 9,000 stock options, exercisable at par value of Rs 5/- to the Independent Directors of the Co. under "Dr. Reddy's ESOS 2002" & "Dr. Reddy's Employees ADR Stock Option Scheme, 2007". |
| Jan 20, 2009 | Quarterly Results | - |
| Oct 23, 2008 | Quarterly Results & Amalgamation | To consider a Scheme of Amalgamation in terms of which Periecan Pharma Pvt. Ltd, a wholly owned subsidiary of the Company will be amalgamated with Dr. Reddy's Laboratories Ltd. |
| Jul 21, 2008 | Quarterly Results | - |
| May 20, 2008 | Audited Results & Dividend | - |
| Jan 25, 2008 | Quarterly Results | - |
| Oct 24, 2007 | Quarterly Results | - |
| Jul 23, 2007 | Quarterly Results | - |
| May 18, 2007 | Audited Results & Dividend | - |
| Jan 22, 2007 | Quarterly Results | - |
| Oct 27, 2006 | Quarterly Results | - |
| Jul 27, 2006 | Quarterly Results | - |
| May 31, 2006 | Accounts & Dividend | - |
| Jan 24, 2006 | Quarterly Results | - |
| Oct 29, 2005 | Quarterly Results | - |
| Jul 26, 2005 | Quarterly Results | - |
| May 06, 2005 | Accounts & Dividend | - |
| Jan 31, 2005 | Quarterly Results | - |
| Oct 26, 2004 | Quarterly Results | - |
| Jul 27, 2004 | Quarterly Results | - |
| Jan 30, 2004 | Quarterly Results | - |
| Oct 28, 2003 | Quarterly Results | - |
| Jul 31, 2003 | Quarterly Results | - |
| May 30, 2003 | Accounts & Dividend | - |
| Jan 28, 2003 | Quarterly Results | - |
| Oct 24, 2002 | Quarterly Results | - |
| Jul 31, 2002 | Quarterly Results | - |
| Jun 04, 2002 | Accounts & Dividend | - |
| Mar 04, 2002 | Interim Dividend | - |
| Jan 29, 2002 | Quarterly Results | - |
| Oct 31, 2001 | Quarterly, H.Y. Results & I. Dividend | - |
| Jul 31, 2001 | Quarterly Results & Others | Stock Split & Employees Stock Option Plan |
| May 30, 2001 | Accounts & Dividend | - |
| Jan 30, 2001 | Quarterly Results | - |
| Oct 30, 2000 | Quarterly Results | - |
| Jul 28, 2000 | Quarterly Results | - |
| Mar 23, 2000 | Interim Dividend and Issue of ADS | - |
| Mar 06, 2000 | Merger | - |
| Oct 20, 1999 | Quarterly Results | - |
| Jul 29, 1999 | Quarterly Results | - |
| Apr 19, 1999 | Accounts & Dividend | - |
| Jan 30, 1999 | Quarterly Results | - |
| Oct 21, 1998 | Quarterly Results | - |
| Apr 27, 1998 | Accounts & Dividend | - |
| May 17, 1997 | Accounts & Dividend. | - |
| Ex-Date | Bonus Ratio | Record Date |
|---|---|---|
| Aug 28, 2006 | 1:1 | 2006-08-29 |
12 Sep 2024
DR.REDDY'S LABORATORIES LTD. - 500124 - Shareholder Meeting / Postal Ballot-Scrutinizer"s Report
Scrutinizer''s Report
12 Sep 2024
DR.REDDY'S LABORATORIES LTD. - 500124 - Shareholder Meeting / Postal Ballot-Outcome of Postal Ballot
Results of voting through Postal Ballot
10 Sep 2024
DR.REDDY'S LABORATORIES LTD. - 500124 - Intimation Under Regulation 30(11) Of SEBI (LODR) Regulations, 2015
Intimation under Regulation 30(11) of SEBI (LODR) Regulations, 2015
06 Sep 2024
US FDA closes inspection of Dr Reddy's API unit
The company's scrip lost0.42 per cent on the BSE on Friday to end at Rs 6669.75
06 Sep 2024
DR.REDDY'S LABORATORIES LTD. - 500124 - Disclosure Under Regulation 30 Of SEBI (LODR) Regulations, 2015
Disclosure under Regulation 30 of SEBI (LODR) Regulations, 2015
05 Sep 2024
DR.REDDY'S LABORATORIES LTD. - 500124 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Issue of letter of confirmation in lieu of share certificate(s) reported to be lost/misplaced
04 Sep 2024
Dr Reddy's, Lupin recall products in US due to manufacturing issues: USFDA
Dr Reddy's Laboratories and Lupin are recalling products in the US due to manufacturing issues, as per the US Food and Drug Administration (USFDA). Dr Reddy's Laboratories Inc, a subsidiary of Hyderabad-based drug firm, is recalling Ibuprofen tablets in multiple strengths, the US health regulator said in its latest enforcement report. Ibuprofen tablets are indicated for pain relief and fever. New Jersey-based Dr Reddy's Laboratories Inc. is recalling 1,03,298 bottles (800 mg); 31,802 bottles (600 mg); and 14,940 bottles (400 mg) of Ibuprofen tablets in the US market, USFDA said. The company is recalling the affected lot due to "Failed impurities/degradation specifications," it added. "Results for unknown impurity were 0.13 per cent and 0.11 per cent, respectively, exceeding the 0.10 per cent specification limit," USFDA noted. The company initiated the Class II nationwide recall on August 6 this year. USFDA stated that Lupin is recalling 4,554 bottles of Cefixime for Oral Suspen
02 Sep 2024
Dr Reddy's declines 3% after China's regulator bans import of ADHD drug
Atomoxetine is used for treating attention deficit hyperactivity disorder (ADHD) in adults and children over six years.
31 Aug 2024
DR.REDDY'S LABORATORIES LTD. - 500124 - Disclosure Under Regulation 30 Of SEBI (LODR) Regulations, 2015
Disclosure under Regulation 30 of SEBI (LODR) Regulations, 2015
30 Aug 2024
DR.REDDY'S LABORATORIES LTD. - 500124 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Schedule of Analyst / Institutional Investor Meeting
